

7101/OE616

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)

09/142970

INTERNATIONAL APPLICATION NO.
PCT/EP98/00294INTERNATIONAL FILING DATE
20 January 1998PRIORITY DATE CLAIMED
21 January 1997

TITLE OF INVENTION

IGA 1 PROTEASE FRAGMENT AS CARRIER PEPTIDE

APPLICANT(S) FOR DO/EO/US

Mark ACHTMAN and Monique MOREAU

Applicant herewith submits to the United States Designated/Elected office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S. C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371 (f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S. C. 371 (b) and PCT Articles 22 and 39 (1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S. C. 371 (c) (2))
- a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
- b. ☒ has been transmitted by the International Bureau
- c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S. C. 371 (c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
- a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
- b. ☐ have been transmitted by the International Bureau.
- c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
- d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c) (3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (unsigned).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.79 and 1.98 (with references).
12. ☐ An assignment document for recording. A **separate** cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
- ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney an/or address letter.
16. ☐ Other items or information:

EXPRESS MAIL CERTIFICATE

Date 9/18/98 Label No. 445426942

I hereby certify that on the date indicated above I
deposited this paper or fee with the U.S. Postal Service
& that it was addressed for delivery to the Commissioner
of Patents & Trademarks, Washington, DC 20231 by
*Express Mail Post Office to Addressee's Order.

Name (Print)

Signature

U.S. APPLICATION NO. (if known sec 37 C.F.R.1.50)

INTERNATIONAL APPLICATION NO.: PCT/EP98/00294

Attorney's Docket N
7101/0E616

17. [X] The following fees are submitted:

Basic National Fee (37 CFR 1.492 (a)(1)-(5)):

Search Report has been prepared by the EPO [X] or JPO []

\$930.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)

\$720.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482)
but international search fee paid to USPTO (37 CFR 1.445 (a) (2))...

\$790.00

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....

\$1,070.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)
and all claims satisfied provisions of PCT Article 33(2)-(4).....

\$98.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$930.00

Surcharge of \$130.00 for furnishing the oath or declaration later than []20 []30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

Claims

Number Filed

Number Extra

Rate

Total Claims

25-20

5

5 X \$22.00

\$110.00

Independent Claims

1 + 2 =

0

X \$80.00

\$

Multiple dependent claims(s) (if applicable)

+ 270

\$

TOTAL OF ABOVE CALCULATIONS =

\$1040.00

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note
37 CFR 1.9, 1.27, 1.28).

\$

SUBTOTAL =

\$1040.00

Processing fee of \$130.00 for furnishing the English translation later the [] 20 [] 39
months from the earliest claimed priority date (37 CFR 1.492(f)).

+

\$

TOTAL NATIONAL FEE =

\$1040.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). the assignment must be accompanied by an
appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

+

\$

TOTAL FEES ENCLOSED =

\$1040.00

Amount to be:
refunded

\$C

charged

\$

a. [X] A check in the amount of \$1,040.00 to cover the above fees is enclosed.

b. [] Please charge my Deposit Account No.04-0100 in the amount of \$ to cover the above fees.

c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit
Account No. 04-0100. A duplicate copy of this sheet is enclosed.**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed
and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Bert J. Lewen

Darby & Darby P.C.

805 Third Avenue

New York, New York 10022-7513

SIGNATURE

NAME Robert C. Sullivan, Jr.

REGISTRATION NO. 30,499

09/142970

405 Rec'd PCT/PTO 18 SEP 1998

EXPRESS MAIL CERTIFICATE

Date 9/18/98 Label No. em 4 45426942

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

D Beck

Name (Print)

D Beck

Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00
OR CREDIT ANY EXCESS IN FUTURE FEES DUE
WITH RESPECT TO THIS APPLICATION TO OUR
DEPOSIT ACCOUNT NO. 04-0100

DARBY & DARBY P.C.

805 Third Avenue
New York, New York 10022
212-527-7700

File No: 7101/0E616

In Re Application of: Mark ACHTMAN
Monique MOREAU

For: IGA 1 PROTEASE FRAGMENT AS CARRIER PEPTIDE

Serial No.: To be assigned
(U.S. National Phase of International Application No. PCT/EP98/00 294 filed
January 20, 1998)

Filed: Concurrently herewith

PRELIMINARY AMENDMENT

Hon. Commissioner of
Box PCT
Patents and Trademarks
Washington, DC 20231
Attention: DO/EO/US

Sir:

Prior to examination, please amend the above-identified patent application:

IN THE SPECIFICATION:

Page 1, before the first full paragraph, insert the heading --FIELD OF THE INVENTION--.

Page 1, before the second paragraph, insert the heading --BACKGROUND OF THE INVENTION--.

Page 2, after the second full paragraph, insert the heading --SUMMARY OF THE INVENTION--;

Page 2, after the third full paragraph, insert the heading --DETAILED DESCRIPTION OF THE INVENTION--.

Page 20, before the first full paragraph, please delete "Claims"

Page 20, before the first full paragraph, please insert the heading --WHAT IS CLAIMED IS:--

IN THE CLAIMS:

Please cancel claims 1-25.

Please add new claims 26-50 as follows.

- 26. (New) A peptide having 40 to 200 amino acid residues, wherein the peptide comprises an amino acid sequence having 40 or more amino acids that are identical or homologous to an amino acid sequence selected from the group consisting of amino acid sequences:
- of SEQ ID NO 1, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
 - of SEQ ID NO 2, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
 - of SEQ ID NO 3, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;

- d. of SEQ ID NO 4, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104; and
 - e. of SEQ ID NO 5, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104.--
- 27. (New) The peptide of claim 26, wherein the peptide comprises at least 40 amino acids of the amino acid sequence shown in SEQ ID NO 1, beginning with the amino acid residue in any one of the positions 1 to 5 and ending with an amino acid residue in any one of positions 40 to 104, or a homologous sequence.--
- 28. (New) The peptide of claim 26, wherein the peptide comprises a sequence of at least 40 amino acids that is at least 85% identical to any one of the amino acid sequences of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, and SEQ ID NO 5.--
- 29. (New) The peptide of claim 26, wherein the peptide comprises a sequence of at least 70 amino acid residues having an amino acid sequence that is identical or homologous to an amino acid sequence of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, or SEQ ID NO 5 beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of the positions 70 to 104.--
- 30. (New) The peptide of claim 26, wherein the peptide comprises a sequence of at least 100 amino acid residues having an amino acid sequence that is identical or homologous to an amino acid sequence of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, or SEQ ID NO 5 beginning with the amino acid residue in any one of the positions 1 to 5 and ending with the amino acid residue in any one of the positions 100 to 104.--
- 31. (New) The peptide of claim 26, wherein the peptide comprises the amino acid sequence of SEQ ID NO 1.--

- 32. (New) The peptide of claim 26, wherein the peptide comprises an amino acid sequence which is at least 85% identical to the amino acid sequence of SEQ ID NO 1.--
- 33. (New) The peptide of claim 26, wherein the peptide further comprises an additional cysteine residue.--
- 34. (New) The peptide of claim 33, wherein the cysteine residue is located at one terminus of the peptide sequence.--
- 35. (New) The peptide of claim 26, wherein the peptide is produced by organic synthesis.--
- 36. (New) The peptide of claim 35, wherein the organic synthesis comprises using Fmoc or Boc chemistry and an automated peptide synthesizer.--
- 37. (New) The peptide of claim 35, wherein the organic synthesis comprises using FastMoc chemistry.--
- 38. (New) The peptide of claim 35, wherein the organic synthesis is carried out under conditions such that the amino groups of the amino acids are protected with 9-fluorenylmethyloxycarbonyl (Fmoc) groups and side groups are protected with the following groups: the carboxyl or hydroxyl groups, respectively, of aspartic acid, glutamic acid, serine, threonine and tyrosine with O-t-butyl; the amino or imino group, respectively, of histidine, asparagine and glutamine with trityl; the amino group of lysine with t-butyloxycarbonyl; and the imino group of arginine with PMC and wherein the activation and coupling is done in the presence of HBTU/diisopropylethylamine, and wherein the peptide is deprotected with piperidine and the final product is N-terminally acetylated using acetic anhydride.--
- 39. (New) The peptide of claim 35, wherein the organic synthesis comprises using double couplings and acetylation with acetic anhydride at cycles 1-2, 4, 10-13, 17, 27, 32, 49, 59, 66, 75-78, 84-85, 88, 96-97 and 104-105.--

- 40. (New) The peptide of claim 35, wherein the organic synthesis comprises using TentaGel S RAM Spezial as a solid phase.--
- 41. (New) The peptide of claim 35, wherein the organic synthesis comprises adding a cysteine unit to the N-terminus or the C-terminus of the peptide.--
- 42. (New) A method of forming a carrier-antigen complex, comprising linking the peptide of claim 1 to an antigen, thereby forming a carrier-antigen conjugate.--
- 43. (New) The method of claim 42, wherein the antigen is selected from the group of polysaccharides consisting of lipopolysaccharides, O-antigens, bacterial membrane polysaccharides, capsular membrane polysaccharides and fungal membrane polysaccharides.--
- 44. (New) The method of claim 42, wherein the antigen is Polysaccharide C of *Neisseria meningitidis*.--
- 45. (New) A conjugate comprising the peptide of claim 26 and an immunoreactive molecule.
--
- 46. (New) The conjugate of claim 45, wherein the immunoreactive molecule is a polysaccharide.--
- 47. (New) The conjugate of claim 45, further comprising an additional cysteine residue in the peptide, a bifunctional linker and a polysaccharide, wherein the peptide is bonded to the linker via the thiol group of the cysteine and the polysaccharide is bonded to the other functional group of the linker via a hydroxy, carboxy, or amino group.--
- 48. (New) The conjugate of claim 45, wherein the polysaccharide is Polysaccharide C of *Neisseria meningitidis*.--

--49. (New) The conjugate of claim 45, wherein the conjugate comprises one mole of peptide per 50 to 1 moles of polysaccharide.--

--50. (New) A vaccine comprising the conjugate of claim 45 and a conventional carrier, excipient, or diluent.--

REMARKS

The specification has been amended to provide proper headings in accordance with U.S. practice.

The claims have been amended to eliminate multiple claim dependencies.

Entry of this Amendment is respectfully requested.

Respectfully submitted,



Robert C. Sullivan, Jr.
Registration No. 30,499
Attorney for Applicants

Darby & Darby, P.C.
805 Third Avenue
New York, New York 10022
(212) 527-7700

07 Rec'd PCT/PTO 02 APR 1999

EXPRESS MAIL CERTIFICATION

DATE: 4/2/99 LABEL NO.: Em4 45424867

I hereby certify that on the date indicated above I deposited this paper and/or fee with the U.S. Postal Service & that it was addressed for delivery to: Commissioner of Patents & Trademarks, Washington, DC 20231, by "Express Mail Post Office to Addressee" service.

D B Peck

Name

[Signature]
Signature

Docket No.: 7101/OE616

In re Application of: Mark ACHTMAN et al

Serial No: 09/142,970

Examiner : n/a

Filed: September 18, 1998

Art Unit: n/a

For: IGA 1 PROTEASE FRAGMENT AS CARRIER PEPTIDE

Hon. Commissioner of
Patents and Trademarks
Box PCT
Washington, DC 20231
Attn.: DO/EO/US

Sir:

AMENDMENT

Please amend the above-identified application as follows.

In the Specification:

After page 19 and before the claims, please insert the Sequence Listing attached hereto as **Exhibit A**. Please delete the pages designated 1/4, 2/4, 3/4, 4/4 which are replaced by this amendment. Please renumber the pages appropriately.

REMARKS

A diskette is enclosed which includes the required sequence listing for the above-referenced application. A paper copy of the file is submitted with the application pursuant to 37 C.F.R. 1.821(c).


In re Appn. of Mark Achtman et al.
Serial No. 09/142,970
Filed: 09/18/1998

The content of the attached paper entitled "SEQUENCE LISTING" and of the accompanying identically labeled diskette are the same. Further, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification as originally filed.

Consideration of this Amendment and the enclosed diskette and paper are respectfully requested.

Dated: April 2, 1999

Respectfully submitted,



Adam M. Goodman
Reg. No. 43,640
Attorney for Applicant(s)

DARBY & DARBY P.C.
805 Third Avenue
New York, New York 10022
212-527-7700

7101/OE616/LXH0315.WPD;1

IGA1 PROTEASE FRAGMENT AS CARRIER PEPTIDE

The present invention is concerned with a new peptide, its use as a carrier for a conjugate, particularly in combination with a polysaccharide, and a process for producing the peptide as well as vaccines comprising said peptide.

Polysaccharides are present as capsules in gram-positive and gram-negative bacteria and as a constituent of the cell wall of bacteria and fungi. Various species of the genera *Neisseria*, *Streptococcus*, *Klebsiella*, *Salmonella*, *Shigella* and *Haemophilus* are pathogenic and are responsible for various human diseases, for example epidemic meningitis, otitis, pneumonia and diarrhoea. These diseases represent a serious global childhood public health problem and therefore, it is important to have a prophylaxis against these diseases.

The polysaccharide macromolecules are comprised of saccharide units which can mediate immunogenicity. Therefore, bacterial polysaccharides or parts thereof have been used for the immunisation of humans. Although, these vaccines are immunogenic in children and adults and can induce protective antibodies, they are not suitable to protect infants because they can only elicit a T-cell independent immune response. Thus, the contact with capsular polysaccharides does not induce a memory response and does not result in a persistent protection. Moreover, it is not possible to elicit an immune response in infants.

To overcome the problem of a T-cell independent immune response, a covalent conjugation of polysaccharides as T-independent antigens to protein carriers as T-dependent antigens has been used and found successful in overcoming this deficiency. Immunisation with such conjugates elicits a T-cell dependent antibody response. However, the choice of carrier proteins which are useful for humans is very restricted, and in most cases, polysaccharides have been coupled to tetanus

toxoid, cholera toxoid or diphtheria toxoid. The unlimited or excessive use of these toxoids as carriers is thought to suppress subsequent responses to a polysaccharide coupled to this type of carrier. This suppression of immune response by pre-existing antibodies to the carrier is expected to become a problem in the future.

A further problem which limited the choice of a new carrier protein with regard to this type of conjugate is that the protein has to be non-toxic or detoxified.

Furthermore, known peptide-polysaccharide conjugates suffer from the disadvantage that it is necessary to use an adjuvant to enhance the immune response. However, many known adjuvants are not applicable for humans because they can elicit an inflammatory response. To date, only one adjuvant is permitted for humans: aluminum gel.

Therefore, it was the object of the present invention to provide new carrier molecules which are highly immunogenic, can elicit a T-cell dependent immune response, result in a long-persisting memory in mammals and possibly avoid the use of adjuvants. This object and further objects which will become apparent from the following description are achieved by the use of a novel peptide having at least 40 amino acids.

Therefore, according to a first aspect the present invention provides a peptide having 40 to 200 amino acid residues which comprises at least 40 amino acids of an amino acid sequence as shown in SEQ ID No 1, beginning with the amino acid in any one of positions 1 to 5 and ending with an amino acid in any one of positions 40 to 104 or a homologous sequence.

In a further aspect of the present invention these novel peptides are used as carrier for a conjugate.

Surprisingly, it has been found that a peptide comprising at least 40 N-terminal amino acids of one of SEQ ID No 1, 2, 3, 4 or 5, which are part of an IgA1 protease from *Neisseria* or a

homologous sequence, could be used as carrier for an antigen to elicit a T-cell dependent immune response with long persistence even without the use of adjuvant. It was not foreseeable that such a small peptide could be useful as a carrier for an immunogenic conjugate.

The use of this small peptide has many advantages with regard to those carriers used to date. Being only a small peptide, it can be produced synthetically, it can be conjugated to all types of compounds which are used as immunogens, such as polysaccharides and is especially useful in combination with a polysaccharide from *Neisseria*, particularly from *N. meningitidis*, or *Haemophilus*, particularly *H. influenzae*. Therefore, it is useful for producing vaccines for infants as well as for young children and adults.

The peptide of the present invention is part of an IgA1 protease produced by pathogenic bacteria of the genus *Neisseria*. IgA1 protease is an enzyme which degrades IgA1 antibodies produced by the host as protection against the bacteria. Although it was known that IgA1 proteases can elicit an immune response, the use of such a protease as carrier has not been contemplated because on the one hand, it is a large molecule, and on the other hand, it has a negative influence on the immune system of the human to be immunised. In contrast thereto, the peptide does not have this enzymatic effect.

The peptide of the present invention comprises at least 40 amino acids, preferably at least 50 amino acids, more preferably at least 70 amino acids, and most preferably all 104 amino acids of one of the sequences of SEQ ID No 1, 2, 3, 4 or 5 or a homologous sequence thereof. Most preferably, the peptide is the 104mer of SEQ ID No 1.

The peptide can also have more than 104 amino acids. The sequences illustrated in SEQ ID No. 1, 2, 3, 4 and 5 can be extended by further amino acids which do not interfere with other amino acids, affect the T-epitope or alter the structure

of the first 40 N-terminal amino acids of the peptide. The sequence can be extended on the N-terminus as well as on the carboxy terminus. The peptide must have at least 40 amino acids and not more than about 200 amino acids. If the peptide has less than 40 amino acids, it is not suitable as carrier and a persistent immunisation is unlikely to occur with it as carrier. On the other hand, a peptide having more than 200 amino acids is difficult to synthesize. It has been found that a peptide having more than 70 amino acids has improved antigenicity, and most preferred is a peptide having 104 amino acids with the sequence of SEQ ID No 1. The said sequence is part of an IgA1 protease from *Neisseria meningitidis*, serogroup A, subgroup III, strain Z3906 and is identical to a sequence with Genbank accession X82474.

The peptide of the present invention is preferably identical or homologous to a peptide having the amino acid sequence of one of SEQ ID No 1, 2, 3, 4 or 5. Preferably, the peptide is at least 85% identical to one of the above-mentioned amino acid sequences, more preferably it is 90% identical and particularly preferred is 95% identical to the above-mentioned amino acid sequences. In the most preferred embodiment, the peptide is 100% identical to the above-mentioned amino acid sequences, particularly to SEQ ID No 1.

A peptide having a sequence homologous to one of the sequences shown in SEQ ID No 1, 2, 3, 4 or 5 is also within the scope of the present invention. SEQ ID No 2 is a sequence from *N. meningitidis*, serogroup C, ET-37 complex, strain Z4400. SEQ ID No 3 is a sequence from *N. meningitidis*, serogroup A, subgroup III, strain Z3524. SEQ ID No 4 is derived from sequence S09386 from SwissProt. SEQ ID No 5 is a sequence from *N. gonorrhoeae*, strain MS11, published in EP-A 254090 and identical to GenBank accession number A02796.

The term "homologous", as it is used in the present description and claims, refers to a sequence that is at least 80% identical to the respective sequence. The homology of a peptide is typically measured using sequence analysis software (e.g. sequence analysis software package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI, 53705). Similar amino acid sequences are aligned to obtain the maximum degree of homology. To this end, it may be necessary to artificially introduce gaps into the sequence. Once optimal alignment has been set up, the degree of homology is established by recording all of the positions in which the amino acids of both sequences are identical, relative to the total number of positions.

Analogous of the peptide of the present invention accordingly are also within the scope of the present invention. An "analog" peptide is an alternate form of a peptide that is characterized as having a substitution, deletion or addition of one or more amino acids that does not alter the biological function of the polypeptide. The biological function of the peptide of the present invention is eliciting a T-dependent immune response when used as carrier together with an antigen.

In a preferred embodiment, the peptide of the present invention comprises additionally a cysteine residue. The cysteine residue can be located either at the carboxy terminus, at the N-terminus or within the amino acid chain by substituting one of the amino acids in the sequence by a cysteine residue. This substitution can be done at all places with the proviso that the T-dependent epitope is not destroyed or affected. Preferably, the cysteine is added at one of the termini. As the peptide having a sequence according to one of SEQ ID No 1, 2, 3, 4 or 5 does not contain any cysteine, the introduction of a cysteine is particularly useful, because it does not destroy or interfere with the structure of the peptide. The cysteine is introduced for a stable coupling with

a linker molecule. It is also possible to couple the peptide via other functional groups, for example the amino group of a lysine residue or the carboxylic group of a glutamic or aspartic acid group.

The peptide of the present invention can be produced by microbiological methods as well as by organic synthesis. In a preferred embodiment, the peptide is produced either using recombinant techniques or by synthesis. For the recombinant production of the peptide a polynucleotide is provided on the basis of the amino acid sequence given in one of SEQ ID No 1, 2, 3, 4 or 5 and the peptide is produced according to well-known techniques of genetic engineering.

The other preferred method for producing the peptide of the present invention is via an organic synthesis. The peptide can be synthesized by methods well-known to the skilled artisan. For example, some smaller fragments can be produced by coupling the appropriate amino acids. The complete peptide is then obtained by coupling these fragments.

Therefore, a further aspect of the present invention is a process for producing the peptide using an organic synthesis. In a preferred embodiment the complete peptide is produced by a solid phase synthesis preferably using Fmoc or Boc chemistry. It is especially preferred to carry out the synthesis with an automated peptide synthesizer and to use FastMoc chemistry.

In a particularly preferred embodiment, the 104mer of SEQ ID No 1, the sequence of which is outlined above, is synthesized using an automated peptide synthesizer and FastMoc chemistry wherein the solid phase is TentaGel S RAM Spezial, wherein the amino acids are FMoc protected and the side groups preferably are protected as follows: the carboxyl or hydroxyl group, respectively, of aspartic acid, glutamic acid, serine, threonine and tyrosine with O-t-butyl; the amino or imino group, respectively, of histidine, asparagine and glutamine with trityl; the amino group of lysine with t-butyloxycarbonyl;

and the imino group of arginine with PMC. At cycles 1-2, 4, 10-13, 17, 27, 32, 49, 59, 66, 75-78, 84-85, 88, 96-97 and 104-105 double couplings should be performed and free amino groups are blocked by acetylation with acetic anhydride. The activation and coupling is preferably done in the presence of HBTU/diisopropylethylamine. After piperidine deprotection the final product is N-terminally acetylated using acetic anhydride.

The above outlined process, of course, may also be employed if the peptide of the present invention has less than 104 amino acids or more than 104 amino acids. In the former case, the process is varied by omitting some of the first cycles whereas in the latter case, the process is varied by adding some further cycles to introduce further amino acids. If the peptide is a homologous peptide or has a sequence as identified in one of SEQ ID No 2, 3, 4 or 5 or is homologous to one of these sequences, having some different amino acids, the process can be adapted accordingly by using the appropriate amino acid in protected form for the respective cycle.

The peptide of the present invention is a useful carrier for immunoreactive molecules such as polysaccharides. The peptide provides T-cell epitopes which are necessary for generating an immunologic "memory" and therefore generally can be used as carrier for all known immunoreactive molecules to produce conjugates which can be used as efficient vaccines.

In a preferred embodiment of the present invention, the peptide is used as carrier for a polysaccharide to elicit an immune response. The polysaccharide can be any polysaccharide which is known to be immunogenic in mammals, especially humans. The term "polysaccharide" also embraces smaller polysaccharides which are immunogenic and which are sometimes referred to as oligosaccharides. Polysaccharides which can be used as part of the conjugate are capsular polysaccharides, lipopolysaccharides, O-antigens, bacterial or fungal membrane polysaccharides or depolymerized parts thereof, for example

polysaccharide C of *Neisseria meningitidis*. The polysaccharide can have a molecular weight in the range of 10,000 to 500,000. Natural occurring polysaccharides normally have a molecular weight in the range of 100,000 to 500,000 whereas depolymerized forms thereof may have a lower molecular weight as low as 10,000.

A further object of the present invention is a conjugate comprising a peptide as described above and an immunoreactive molecule. In a preferred embodiment, the immunoreactive molecule is coupled to the peptide via a linker. The linker provides functional groups at both ends which provide for the bonding to the peptide and the antigenic molecule, respectively. Both functional groups are connected to a bridge, the length of which is chosen so that both parts are presented to the immune system in an optimal manner. The bridge should not be too short as otherwise steric hindrance could occur. On the other hand, it should not be too long so as not to interfere with the structure of both parts. It is preferred that the length of the bridge between both functional groups is 2 to 20 atoms selected from C, N, O and S. More preferably the bridge is selected from C₂-C₈-alkylene, phenylene, C₇-C₁₂-aralkylene, C₂-C₆-alkanoyloxy and benzylcarbonyloxy.

The functional groups used for the coupling to the peptide and the polysaccharide are those functional groups which are commonly used in this field. A review of coupling methods is found in W.E. Dick and M.Beurret in *Conjugates Vaccines*, J.M. Cruse, R.E. Lewis Jr Eds, Contrib. Microbiol. Immunol. Basel, Karger (1989) 10:48. The peptide is bonded to the linker via a functional group provided by one of the amino acids, for example an amino, a carboxy or hydroxy group. In a preferred embodiment, the peptide is bonded to the linker via the thiol group provided by a cysteine residue. The immunoreactive molecule can be bonded to the spacer via functional groups which are available. In a preferred embodi-

ment when using a polysaccharide as immunoreactive molecule, hydroxy, amino or carboxy groups which are present or have been introduced in the saccharide units are used for the coupling. Preferably, the linker is bonded to the hydroxy groups of the polysaccharide via an ether, ester, amide or carbamate linkage, to the amino groups via a N-OH-succinimidyl linkage and/or to the carboxyl groups via an ester linkage. The conjugate of the present invention can be produced using methods known to the skilled artisan.

The immune response which is elicited by the conjugate of the present invention is dependent on the number and availability of T-cell dependent and B-cell dependent epitopes and their ratio. In the conjugate of the present invention the T-cell dependent epitopes are provided by the peptide whereas the B-cell dependent epitopes are contributed by the polysaccharide. Therefore, the ratio of both parts of the conjugate is an essential feature. Thus, the ratio of both components should be adjusted so that not too little of either sort of molecule is present. It has been found by the inventors of the present invention that good results can be obtained if about 1 mol of peptide is present per 1 to 50 moles, preferably 3 to 30 moles and most preferably 5 to 20 moles of repeating units of the polysaccharide. If less than 1 mol of peptide per 50 moles of repeating units is present, no immune response can be detected because there are not enough peptide molecules to induce a persistent immune response. On the other hand, if more than 1 mol of peptide per mol of repeating units are present, the results are also not satisfying because too much of the polysaccharide is sterically hindered to elicit an immune response. The term "repeating units" refers to units within the polysaccharides which are composed of 1 to 7 different saccharides and differ with regard to the nature of saccharide, linkage position and the anomeric configuration of the saccharide.

A further aspect of the present invention is a vaccine which comprises a conjugate according to the present invention together with conventional carriers, excipients and diluents. The conjugate is mixed with or diluted in or dissolved in a conventional carrier, excipient or diluent as it is known in this field in an efficient amount. This vaccine can be used to immunise infants, children and adults. It is especially useful for the control of epidemically occurring diseases which are caused by *Neisseria meningitidis* or other bacteria carrying capsular polysaccharides. The use of the vaccine of the present invention results in high antibody titers.

Example 1

Production of a synthetic 105mer peptide having the following sequence (SEQ ID No. 1 + N-terminal cysteine):

Cys Leu Tyr Tyr Lys Asn Tyr Arg Tyr Tyr Ala Leu Lys Ser Gly Gly
Ser Val Asn Ala Pro Met Pro Glu Asn Gly Gln Thr Glu Asn Asn Asp
Trp Ile Leu Met Gly Ser Thr Gln Glu Glu Ala Lys Lys Asn Ala Met
Asn His Lys Asn Asn Gln Arg Ile Ser Gly Phe Ser Gly Phe Phe Gly
Glu Glu Asn Gly Lys Gly His Asn Gly Ala Leu Asn Leu Asn Phe Asn
Gly Lys Ser Ala Gln Asn Arg Phe Leu Leu Thr Gly Gly Thr Asn Leu
Asn Gly Lys Ile Ser Val Thr Gln Gly

The peptide was synthesised using FastMoc chemistry with an automated peptide synthesiser (model 431A, Applied Biosystems). The solid phase was a Rink resin (0.13 mM TentaGel S RAM Spezial, 0.15 mM g⁻¹, Rapp Polymere, Tübingen, Germany) which yields a C-terminal amide capped peptide. The amino groups of the amino acids used for the synthesis were protected with 9-fluorenylmethyloxycarbonyl (Fmoc) groups and side groups were protected with the following groups:

for the carboxyl or hydroxyl group, respectively, of aspartic acid, glutamic acid, serine, threonine and tyrosine: the O-t-butyl group;

for the amino or imino group, respectively, of histidine, asparagine and glutamine: the trityl group;

for the amino group of lysine: the t-butyloxycarbonyl group;

and for the imino group of arginine: the PMC group.

The activation and coupling were done in the presence of 2-(1 H-benzotriazol-1-yl)-1,3,3-tetramethyluronium hexafluorophosphate (HBTU)/diisopropylethylamine. At cycles 1-2, 4, 10-13, 17, 27, 32, 49, 59, 66, 75-78, 84-85, 88, 96-97 and 104-105, double coupling was performed and free amino groups were blocked by acetylation with acetic anhydride. After the last cycle, the peptide was deprotected with piperidine and the final product was N-terminally acetylated using acetic anhydride.

The side-chain deprotection and cleavage from the resin support was carried out with 2.1 % (v/v) 1,2-ethanedithiol, 4.2 % (v/v) thioanisol, 4.2% (v/v) water, 6.2 % phenol (v/v) and 83% (v/v) trifluoroacetic acid (TFA) for 3 hours at room temperature. The resin was removed by filtration and triethylsilane was added in dropwise fashion until the solution was colourless. The solution was then incubated 3 more hours at room temperature. 360 mg crude peptide was recovered after precipitation with t-butylmethylether followed by centrifugation and lyophilisation. 130 mg of the crude peptide was dissolved in 40 ml 50 mM ethylmorpholine, pH 8.3 containing 50 mM dithiothreitol and incubated overnight at room temperature. The pH was adjusted to 3.5 with 10% TFA and the peptide was purified by reverse phase HPLC (Pep-S, C2/C18, 100 Å pore size, 12 µm 22.5 mm x 25 cm, Pharmacia) using a gradient (25 to 45% (v/v)) of acetonitrile, 0.1% TFA (10 ml min⁻¹, gradient of 0.33% min⁻¹). The peptide eluted as one peak at

about 25% acetonitrile, and the peak was lyophilized (73 mg) before further use. An analysis by HPLC and mass spectrometry showed that over 65% of the final product corresponded to the desired sequence. The N-terminal sequence was confirmed by N-terminal Edman sequencing of the sample removed before N-terminal acetylation.

Example 2

Preparation of a polysaccharide peptide conjugate

A dry powder of capsular polysaccharide from *Neisseria meningitidis* serogroup C, referred to as polysaccharide C in the following, was obtained by an extraction process as described by E. Gotschlich et al. in J. Exp. Med., No 129 (1969), p 1349 - 1365. 100 mg of polysaccharide C were dissolved in 0.2 M NaCl to a final concentration of 11.1 mg/ml (solution A). In parallel, a solution of 0.2 M adipic acid dihydrazide (ADH) in 0.2 M NaCl was prepared (solution B). A 0.5 M solution of ethyl dimethyl aminopropyl carbodiimide (EDAC) in 0.2 M NaCl was also prepared (solution C). 9 ml of solution of A, 10 ml of solution B and 1 ml of solution C are mixed together to give a preparation containing 5 mg/ml of polysaccharide C, 0.125 M ADH and 0.025 M EDAC. 0.1 M HCl was added to adjust the pH to 6.5; this pH was maintained during the entire reaction period of 45 minutes. The temperature was about 20°C.

Reaction was stopped by 40 µl 0.1 N NaOH which raised the pH to 7.1. The reaction mixture was dialysed against 0.5 M NaCl, 10 mM phosphate and then water and subsequently lyophilized.

The size of the derivatized polysaccharide C was controlled on a HPLC exclusion column TSK 4000 (manufacturer Tosohaas). The results demonstrated that no depolymerization had occurred in the course of the derivatization.

During the derivatization, about 3.4% of repeat units were derivatized with an NH_2 group.

The lyophilized product was dissolved in 0.02 M phosphate buffer, pH 7, to a concentration of 6.25 mg/ml and degassed. Succinimidyl maleimido butyrate (GMBS) was dissolved in dimethylsulfoxide (DMSO) under nitrogen at a concentration of 25 mg/ml and then added to derivatised polysaccharide C in equal amount. The reaction mixture was stirred for 90 minutes at room temperature under nitrogen. The activated polysaccharide C was purified by sephadex G50 exclusion column chromatography. The excluded fraction was recovered and concentrated to about 7.5 mg/ml by ultrafiltration (30K Amicon membrane). The concentrated solution was degassed.

20 mg of the peptide as obtained in example 1 was dissolved in water at a concentration of 10 mg/ml under nitrogen. 1.5 ml of the peptide solution was added to 1.2 ml of the preparation containing the activated polysaccharide C, so that the ratio (maleimido residues)/(thiol residues) equaled 2. The reaction mixtures were maintained over night under stirring at room temperature. Then the unreacted maleimido residues were inactivated by adding 0.010 ml mercaptoethanol.

The conjugated product was purified on a 4BCL Sepharose column. The eluted fractions were assayed for the presence of saccharides (sialic acid) and peptides. Fractions responding positively in both assays were pooled.

The amount of sialic acid residues was determined according to the dosage method described in Svennerholm L., Biochim. Biophys. Acta (1957) 24 : 604, and the amount of peptide was determined according to the method of Lowry et al, J. Biol. Chem. (1951) 193 : 265. It was shown that the ratio (peptide)/(repeating units of polysaccharide C) mole/mole was 1:18 (corresponding to a ratio weight/weight of 1.8:1).

Example 3

A dry powder of capsular polysaccharide from *Streptococcus pneumoniae* type 4, referred to as polysaccharide Pneumo 4 in the following, is obtained by an extraction process as described in the patent WO-A 82/01 995 "Procédé de purification de polysides de *Streptococcus pneumoniae* et vaccins à base de polysides ainsi purifiés". 100 mg of polysaccharide Pneumo 4 were dissolved in 0.2 M NaCl to a final concentration of 11.1 mg/ml (solution A). In parallel, a solution of adipic acid dihydrazide (ADH) in 0.2 M NaCl was prepared in a concentration of 0.25 M (solution B). A solution of ethyl dimethyl aminopropyl carbodiimide (EDAC) in 0.2 M NaCl was also prepared at a concentration of 0.5 M (solution C). 9 ml of solution A, 10 ml of solution B and 1 ml of solution C are mixed together to give a preparation containing 5 mg/ml of polysaccharide Pneumo 4, 0.125 M ADH and 0.025 M EDAC. 1 N HCL was added to a pH of 4.9; this pH was maintained during the entire reaction period of 30 minutes. The temperature was about 25°C.

Reaction was stopped by 0.28 ml N NaOH. The pH was increased to 7.5. The reaction mixture was dialysed against 0.5 M NaCl and then water and subsequently lyophilized.

The size of the derivatized polysaccharide Pneumo 4 was controlled on a HPLC exclusion column TSK 4000 (manufacturer Tosohaas). No depolymerization occurred in the course of the derivatization.

During the derivatization, about 8.2% of repeat units of the polysaccharide Pneumo 4 were derivatized with a $-NH_2$ group.

Lyophilized product was dissolved in 0.05 M NaCl at a concentration of 2.76 mg/ml and degassed. Succinimidyl maleimido butyrate (GMBS) was dissolved in dimethylsulfoxide (DMSO) under nitrogen at a concentration of 25 mg/ml. 1.75 ml of the GMBS solution were added to 16 ml of the polysaccharide

solution under nitrogen. The reaction mixture was left under stirring for 5 hours at room temperature under nitrogen. The activated polysaccharide Pneumo 4 was purified on an exclusion column Sephadex G50. The excluded fraction was recovered and concentrated to about 7 mg/ml on a 30K membrane (Amicon). The concentrated solution was degassed.

20 mg of the peptide as obtained in example 1 were dissolved in 0.1 M NaCl, 0.01 M phosphate buffer pH 7.5, at a concentration of 4.6 mg/ml under nitrogen. On the one hand, 2.2 ml of the peptide solution were added to 1.25 ml of the preparation containing the activated polysaccharide Pneumo 4, so that the ratio (maleimidyl residues)/(thiol groups) equalled 1 (Pneumo 4-peptide-1 conjugate). Reaction mixtures were maintained 6 hours under stirring at room temperature under nitrogen, then overnight at +4°C. Then the unreacted maleimidyl residues were inactivated by adding 0.005 ml mercaptoethanol to each reaction mixture.

The conjugates were purified on a Sepharose 4BCL column. The eluted fractions were assayed for the presence of sugars and peptides. Fractions responding positively in both assays were pooled.

The amount of sugar was determined according to the dosage method described in Dubois et al. Anal. Chem. (1956) 3 : 350, and the amount of peptide was determined according to the method of Lowry et al, J. Biol. Chem. (1951) 193 : 265. The ratio of repeat units of peptide/polysaccharide mole/mole is 1:30 for the Pn 4-peptide-1 conjugate (corresponding to a ratio w/w of 0.4:1).

Example 4

A dry powder of capsular polysaccharide from *Neisseria meningitidis* serogroup A, referred to as polysaccharide A in the following, is obtained by an extraction process as

described by E. Gotschlich et al. in J. Exp. Med., No 129 (1969), p 1349 - 1365 100 mg of polysaccharide A were dissolved in water to a final concentration of 5 mg/ml (solution A). In parallel, a solution of cyanogen bromide (CNBr) in water was prepared in a concentration of 67 mg/ml (solution B). A solution of adipic acid dihydrazide (ADH) in 0.5 M NaHCO₃ was also prepared at a concentration of 150 mg/ml (solution C). 20 ml of solution A and 0.75 ml of solution C were mixed together to give a preparation with a ratio polysaccharide/CNBr weight/weight that equalled 1. 0.1 N NaOH was added to a pH of 10.8; this pH was maintained during the entire reaction period of 60 minutes. The temperature was about 20°C.

Then the pH was decreased to 8.5 by adding 0.15 ml 0.1 N HCL. 1.17 ml of solution C were added so that the ratio ADH/polysaccharide weight/weight equalled 3.5. The pH was maintained during 15 minutes. Then the reaction mixture was left overnight under stirring at +4°C. 0.1 ml 1 N HCl were added to decrease the pH to 7. The reaction mixture was dialysed against 0.5 M NaCl and then water and subsequently lyophilized.

The size of the derivatized polysaccharide A was controlled on a HPLC exclusion column TSK 4000 (manufacturer Tosohaas). No depolymerization occurred in the course of derivatization.

During the derivatization, about 2.5% of repeat units of polysaccharide A were derivatized with a -NH₂ group.

Then the same processes as in example 2 were used to activate the derivatized polysaccharide A and to conjugate the activated polysaccharide A to the peptide as obtained in example 1.

Example 5

Comparison of the conjugate obtained in Example 2 with other products

The utility of the peptide of example 1 as a carrier in a polysaccharide conjugate is demonstrated as follows:

Six-week old NMRI mice received via the sub-cutaneous route one of the following compositions in a volume of 0.5 ml (each injection) and via the intraperitoneal route, in case an adjuvant was used:

(a) 5 µg polysaccharide C (without peptide) at days 1, 15 and 29, in the absence of adjuvant;

(b) 5 µg polysaccharide C (without peptide) together with complete Freund's adjuvant at day 1, and at days 15 and 29 together with incomplete Freund's adjuvant;

(c) 5 µg polysaccharide C and 9 µg peptide together with complete Freund's adjuvant at day 1, and at days 15 and 29 together with incomplete Freund's adjuvant;

(d) the conjugate obtained in example 2 containing 1 µg polysaccharide C and 1,8 µg peptide at days 1, 15 and 29 in the absence of adjuvant;

(e) the conjugate obtained in example 2 containing 5 µg polysaccharide C and 9 µg peptide at days 1, 15 and 29 in the absence of adjuvant;

(f) the conjugate obtained in example 2 containing 5 µg polysaccharide and 9 µg peptide together with complete Freund's adjuvant at day 1, and at days 15 and 29 the conjugate obtained in example 2 together with incomplete Freund's adjuvant; and

(g) a conjugate of 5 µg polysaccharide C together with diphtheria anatoxin.

On days 15, 29 and 43 (calculated from the day of the first immunisation), a sample of blood is collected and the antipolysaccharide C antibodies are titrated by ELISA.

The results are summarized in the following table.

Table 1

Compound injected	Dose of polysaccharide injected (μ g)	Dose of peptide injected (μ g)	Day after immunisation	Sample of blood collected on day	Antibody titer of anti-polysaccharide (ELISA unit)
(b)	5		1 15 29	15 29 43	10 32 115
(b)	5		1 15 29	15 29 43	22 39 74
(c)	5	9	1 15 29	15 29 43	24 34 47
(d)	1	1.8	1 15 29	15 29 43	32 1052 630
(e)	5	9	1 15 29	15 29 43	56 321 516
(f)	5	9	1 15 29	15 29 43	1006 2854 2492
(g)	5		1 15 29	15 29 43	13 1197 1531

The antibody response to non-conjugated polysaccharide C is extremely weak in each case, whereas, the response to polysaccharide C conjugated to either DT or the peptide is satisfactory. With the conjugate of the present invention a booster effect is obtained after the second injection, being an

indication for an immune response. The response of the conjugate polysaccharide C - peptide is equivalent to the response obtained with the conjugate of polysaccharide C - DT.

Example 6

The conjugate prepared in example 3 with a ratio (w/w) of peptide to polysaccharide of 0.4:1 (corresponding to a ratio of mole peptide per moles repeating units of 1:30) was tested in mice using the same protocol as in example 5. It was immunogenic in mice in the presence of adjuvant and resulted in a booster effect after the second injection. The results can be seen from the following table 2.

Table 2

Compound injected	Dose of poly-saccharide injected (µg)	Dose of peptide injected (µg)	Day after immunisation	Sample of blood collected on day	Anti-poly-saccharide Pn4 (ELISA unit)
Pneumo type 4 PS + adjuv.	5		1	15	<10
			15	29	<10
			29	43	<10
Pneumo type 4 PS + peptide + adjuv.	5	1.9	1	15	~18
			15	29	~24
			29	43	<10
Conj. Pn4-peptide-1 + adjuv.	5	1.9	1	15	~61
			15	29	458
			29	43	2601
Saline			1	15	<10
			15	29	<10
			29	43	<10

Claims

1. A peptide having 40 to 200 amino acid residues and comprising at least 40 amino acids of an amino acid sequence as shown in SEQ ID NO 1, beginning with the amino acid residue in any one of positions 1 to 5 and ending with an amino acid residue in any one of positions 40 to 104 or a homologous sequence.

2. A peptide according to claim 1, comprising an amino acid sequence that is identical or homologous to an amino acid sequence selected from the group consisting of the amino acid sequences:

of SEQ ID NO 2, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;

of SEQ ID NO 3, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;

of SEQ ID NO 4, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104; and

of SEQ ID NO 5, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104.

3. A peptide according to claim 1 or claim 2, comprising at least 40 amino acids having an amino acid sequence that is at least 85% identical to any one of the amino acid sequences of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, and SEQ ID NO 5.

4. A peptide according to any one of the preceding claims, comprising at least 70 amino acid residues having an amino acid sequence that is identical or homologous to an amino acid sequence of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, or SEQ ID NO 5 beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of the positions 70 to 104.

5. A peptide according to any one of the preceding claims, comprising at least 100 amino acid residues having an amino acid sequence that is identical or homologous to an amino acid sequence of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, or SEQ ID NO 5 beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of the positions 100 to 104.

6. A peptide according claim 1, having the amino acid sequence of SEQ ID NO 1.

7. A peptide according to claim 1, comprising an amino acid sequence which is at least 85% identical to the amino acid sequence of SEQ ID NO 1.

8. A peptide according to anyone of the preceding claims, comprising additionally a cysteine residue.

9. A peptide according to claim 8, wherein the cysteine residue is located at one terminus of the peptide sequence.

10. Process for producing a peptide according to claim 1 wherein an organic synthesis is used.

11. Process according to claim 10, wherein the synthesis is carried out using Fmoc or Boc chemistry and an automated peptide synthesizer.

12. Process according to claim 11, wherein FastMoc chemistry is used.

13. Process according to any one of claims 10 to 12, wherein the amino groups of the amino acids are protected with 9-fluorenylmethyloxycarbonyl (Fmoc) groups and side groups are protected with the following groups: the carboxyl or hydroxyl group, respectively, of aspartic acid, glutamic acid, serine, threonine and tyrosine with O-t-butyl; the amino or imino group, respectively, of histidine, asparagine and glutamine with trityl; the amino group of lysine with t-butyloxycarbonyl;

and the imino group of arginine with PMC and wherein the activation and coupling is done in the presence of HBTU/diisopropylethylamine, and wherein the peptide is deprotected with piperidine and the final product is N-terminally acetylated using acetic anhydride.

14. Process according to any one of claims 10 or 13, wherein double couplings and acetylation with acetic anhydride are used at cycles 1-2, 4, 10-13, 17, 27, 32, 49, 59, 66, 75-78, 84-85, 88, 96-97 and 104-105.

15. Process according to any one of claims 10 to 14, wherein the solid phase is TentaGel S RAM Spezial.

16. Process according to any one of claims 10 to 15, wherein a cysteine unit is added to the peptide at the N-terminus and/or the C-terminus.

17. Use of a peptide of any one of claims 1 to 9 as carrier for a conjugate.
18. Use of a peptide of any one of claims 1 to 9 as carrier for a polysaccharide selected from lipopolysaccharides, O-antigens, or bacterial, capsular or fungal membrane polysaccharides.
19. Use of a peptide of any one of claims 1 to 9 as carrier for Polysaccharide C of *Neisseria meningitidis*.
20. Conjugate comprising a peptide according to any one of claims 1 to 9 and an immunoreactive molecule.
21. Conjugate according to claim 20, wherein the immunoreactive molecule is a polysaccharide.
22. Conjugate according to claim 20 or 21, comprising the peptide of any one of claims 1 to 9 with an additional cysteine residue, a bifunctional linker and a polysaccharide, wherein the peptide is bonded to the linker via the thiol group of the cysteine and the polysaccharide is bonded to the other functional group of the linker via a hydroxy, carboxy or amino group.
23. Conjugate according to any one of claims 20 to 22, wherein the polysaccharide is Polysaccharide C of *Neisseria meningitidis*.
24. Conjugate according to any one of claims 20 to 23, wherein one mole of peptide per 50 to 1 moles of repeating units of the polysaccharide is present.

25. Vaccine comprising the conjugate of any one of claims 20 to 24 together with conventional carriers, excipients and/or diluents.

1/4

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Neisseria meningitidis*

(B) STRAIN: Serogroup A, subgroup III, strain Z3524

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

```

Leu Tyr Tyr Lys Asn Tyr Arg Tyr Tyr Ala Leu Lys Ser Gly Gly Ser
1          5          10          15
Val Asn Ala Pro Met Pro Glu Asn Gly Gln Thr Glu Asn Asn Asp Trp
          20          25          30
Val Phe Met Gly Tyr Lys Gln Glu Glu Ala Gln Lys Asn Ala Met Asn
          35          40          45
His Lys Asn Asn Gln Arg Ile Ser Gly Phe Ser Gly Phe Phe Gly Glu
          50          55          60
Glu Asn Gly Lys Gly His Asn Gly Ala Leu Asn Leu Asn Phe Asn Gly
65          70          75          80
Lys Ser Ala Gln Asn Arg Phe Leu Leu Thr Gly Gly Thr Asn Leu Asn
          85          90          95
Gly Lys Ile Ser Val Thr Gln Gly
          100

```

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 104 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Neisseria gonorrhoeae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

```

Leu Tyr Tyr Lys Asn Tyr Arg Tyr Tyr Ala Leu Lys Ser Gly Gly Arg
1          5          10          15
Leu Asn Ala Pro Met Pro Glu Asn Gly Val Ala Glu Asn Asn Asp Trp
          20          25          30
Val Phe Met Gly Tyr Thr Gln Glu Glu Ala Arg Lys Asn Ala Met Asn
          35          40          45
Asn Lys Asn Asn Arg Arg Ile Gly Asp Phe Gly Gly Phe Phe Asp Glu
          50          55          60

```

2/4

50		55		60											
Glu	Asn	Gly	Lys	Gly	His	Asn	Gly	Ala	Leu	Asn	Leu	Asn	Phe	Asn	Gly
65					70					75					80
Lys	Ser	Ala	Gln	Asn	Arg	Phe	Leu	Leu	Thr	Gly	Gly	Thr	Asn	Leu	Asn
			85						90					95	
Gly	Lys	Ile	Ser	Val	Thr	Gln	Gly								
			100												

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 104 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Neisseria meningitidis
- (B) STRAIN: Serogroup C, ET-37 complex, strain Z4400

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Leu	Tyr	Tyr	Lys	Asn	Tyr	Arg	Tyr	Tyr	Ala	Leu	Lys	Ser	Gly	Gly	Ser
1				5					10					15	
Val	Asn	Ala	Pro	Met	Pro	Glu	Asn	Gly	Val	Thr	Glu	Asn	Asn	Asp	Trp
			20					25					30		
Val	Phe	Met	Gly	Tyr	Thr	Gln	Glu	Glu	Ala	Lys	Lys	Asn	Ala	Met	Asn
		35					40					45			
His	Lys	Asn	Asn	Gln	Arg	Ile	Ser	Gly	Phe	Ser	Gly	Phe	Phe	Gly	Glu
	50					55					60				
Glu	Asn	Gly	Lys	Gly	His	Asn	Gly	Ala	Leu	Asn	Leu	Asn	Phe	Asn	Gly
65					70					75					80
Lys	Ser	Ala	Gln	Asn	Arg	Phe	Leu	Leu	Thr	Gly	Gly	Thr	Asn	Leu	Asn
			85						90					95	
Gly	Lys	Ile	Ser	Val	Thr	Gln	Gly								
			100												

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 104 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

3/4

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: Max-Planck-Gesellschaft zur Foerderung der
Wissenschaften e.V. Berlin

(B) STREET: Hofgartenstrasse 2

(C) CITY: Muenchen

(E) COUNTRY: Federal Republic of Germany

(F) POSTAL CODE (ZIP): D-80539

(A) NAME: Pasteur Merieux Serums et Vaccines S.A.

(B) STREET: 58, Avenue Leclerc

(C) CITY: Lyon

(E) COUNTRY: France

(F) POSTAL CODE (ZIP): F-69007

(ii) TITLE OF INVENTION: Carrier Peptide

(iii) NUMBER OF SEQUENCES: 5

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 104 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Neisseria meningitidis

(B) STRAIN: Serogroup A, subgroup III, strain Z3906

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Leu Tyr Tyr Lys Asn Tyr Arg Tyr Tyr Ala Leu Lys Ser Gly Gly Ser
1 5 10 15

Val Asn Ala Pro Met Pro Glu Asn Gly Gln Thr Glu Asn Asn Asp Trp
20 25 30

Ile Leu Met Gly Ser Thr Gln Glu Glu Ala Lys Lys Asn Ala Met Asn
35 40 45

His Lys Asn Asn Gln Arg Ile Ser Gly Phe Ser Gly Phe Phe Gly Glu

4/4

Glu Asn Gly Lys Gly His Asn Gly Ala Leu Asn Leu Asn Phe Asn Gly
 65 70 75 80
 Lys Ser Ala Gln Asn Arg Phe Leu Leu Thr Gly Gly Ala Asn Leu Asn
 85 90 95
 Gly Gly Asn Gly Arg Pro Val Lys
 100

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 104 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Neisseria gonorrhoeae*
- (B) STRAIN: Strain MS11

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Leu Tyr Tyr Lys Asn Tyr Arg Tyr Tyr Ala Leu Lys Ser Gly Gly Arg
 1 5 10 15
 Leu Asn Ala Pro Met Pro Glu Asn Gly Val Ala Glu Asn Asn Asp Trp
 20 25 30
 Ile Phe Met Gly Tyr Thr Gln Glu Glu Ala Arg Lys Asn Ala Met Asn
 35 40 45
 His Lys Asn Asn Arg Arg Ile Gly Asp Phe Gly Gly Phe Phe Asp Glu
 50 55 60
 Glu Asn Gly Lys Gly His Asn Gly Ala Leu Asn Leu Asn Phe Asn Gly
 65 70 75 80
 Lys Ser Ala Gln Asn Arg Phe Leu Leu Thr Gly Gly Ala Asn Leu Asn
 85 90 95
 Gly Lys Ile Ser Val Thr Gln Gly
 100

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

(Includes Reference to PCT International Applications)

ATTORNEY DOCKET NUMBER
7101/OE616

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed for and which a patent is sought on the invention entitled:

IGA 1 PROTEASE FRAGMENT AS CARRIER PEPTIDE

the specification of which (check only one item below):

☐ is attached hereto.☐ was filed as United States application

Serial No.

on

and was amended

on (if applicable).

☒ was filed as PCT international applicationNumber **PCT/EP98/00294**on **20 January 1997**

and was amended under PCT Article 19

on (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (if PCT indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119
EP	97100883.4	21 January 1997	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
PCT	PCT/EP98/00294	20 January 1998	<input type="checkbox"/> YES <input checked="" type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

Combined Declaration for Patent Application and Power of Attorney (Continued) (Includes Reference to PCT International Applications)				ATTY'S DOCKET NUMBER 7101/0E616	
<p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:</p>					
<p>PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:</p>					
U.S. APPLICATIONS			STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
PCT APPLICATIONS DESIGNATING THE U.S.					
PCT APPLICATION NO.	PCT FILING DATE	U.S. SERIAL NUMBER ASSIGNED (if any)			
<p>POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. <u>Morris Relson #15,108, Gordon D. Coplein #19,165, William F. Dudine, Jr. #20,569, Michael J. Sweedler #19,937, S. Peter Ludwig #25,351, Paul Fields #20,298, Joseph B. Lerch #26,936, Melvin C. Garner #26,272, Ethan Horwitz #27,646, Beverly B. Goodwin #28,417, Adda C. Gogoris #29,714, Martin E. Goldstein #20,869, Bert J. Lewen #19,407, Henry Sternberg #22,408, Peter C. Schechter #31,662, Robert Schaffer #31,194, David R. Francescani #25,159, Robert C. Sullivan, Jr. #30,499, and Joseph R. Robinson #33,448</u></p>					
<p>Send Correspondence to:</p> <p style="margin-left: 40px;"><u>Bert J. Lewen</u> DARBY & DARBY P.C. 805 Third Avenue New York, New York 10022-7513</p>			<p>Direct Telephone Calls to: (name and telephone number)</p> <p style="text-align: center;">(212) 527-7700</p>		
2 0 1	FULL NAME OF INVENTOR	FAMILY NAME <u>ACHTMAN</u> 1-00	FIRST GIVEN NAME <u>Mark</u>	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY <u>Berlin</u> DEX	STATE OR FOREIGN COUNTRY <u>Germany</u>	COUNTRY OF CITIZENSHIP <u>Germany</u>	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>Neuenburger Strasse 16</u>	CITY <u>Berlin</u>	STATE & ZIP CODE/COUNTRY <u>Germany D-10696</u>	
2 0 2	FULL NAME OF INVENTOR	FAMILY NAME <u>MOREAU</u> 2-00	FIRST GIVEN NAME <u>Monique</u>	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY <u>Lyon</u> FRX	STATE OR FOREIGN COUNTRY <u>France</u>	COUNTRY OF CITIZENSHIP <u>France</u>	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>rua Garibaldi</u>	CITY <u>Lyon</u>	STATE & ZIP CODE/COUNTRY <u>France F-69007</u>	
2 0 3	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY	
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patents issuing thereon.</p>					
SIGNATURE OF INVENTOR 201 <u>Mark Achtmann</u>		SIGNATURE OF INVENTOR 202		SIGNATURE OF INVENTOR 203	
DATE <u>Feb. 12 1999</u>		DATE		DATE	

Combined Declaration for Patent Application and Power of Attorney (Continued) (Includes Reference to PCT International Applications)				ATTY'S DOCKET NUMBER 7101/0E616	
<p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:</p>					
PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:					
U.S. APPLICATIONS			STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
PCT APPLICATIONS DESIGNATING THE U.S.					
PCT APPLICATION NO	PCT FILING DATE	U.S. SERIAL NUMBER ASSIGNED (if any)			
<p>POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. Morris Relson #15,108, Gordon D. Coplein #19,165, William F. Dudine, Jr. #20,569, Michael J. Sweedler #19,937, S. Peter Ludwig #25,351, Paul Fields #20,298, Joseph B. Lerch #26,936, Melvin C. Garner #26,272, Ethan Horwitz #27,646, Beverly B. Goodwin #28,417, Adda C. Gogoris #29,714, Martin E. Goldstein #20,869, Bert J. Lewen 19,407, Henry Sternberg #22,408, Peter C. Schechter #31,662, Robert Schaffer #31,194, David R. Francescani #25,159, Robert C. Sullivan, Jr. #30,499, and Joseph R. Robinson #33,448</p>					
<p>Send Correspondence to:</p> <p style="text-align: center;">Bert J. Lewen DARBY & DARBY P.C. 805 Third Avenue New York, New York 10022-7513</p>			<p>Direct Telephone Calls to: (name and telephone number)</p> <p style="text-align: center;">(212) 527-7700</p>		
2 0 1	FULL NAME OF INVENTOR	FAMILY NAME ACHTMAN	FIRST GIVEN NAME Mark	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY Berlin	STATE OR FOREIGN COUNTRY Germany	COUNTRY OF CITIZENSHIP Germany	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS Neuenburger Strasse 16	CITY Berlin	STATE & ZIP CODE/COUNTRY Germany D-10696	
2 0 2	FULL NAME OF INVENTOR	FAMILY NAME MOREAU	FIRST GIVEN NAME Monique	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY Lyon	STATE OR FOREIGN COUNTRY France	COUNTRY OF CITIZENSHIP France	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS rue Garibaldi	CITY Lyon	STATE & ZIP CODE/COUNTRY France F-69007	
2 0 3	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY	
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patents issuing thereon.</p>					
SIGNATURE OF INVENTOR 201		SIGNATURE OF INVENTOR 202		SIGNATURE OF INVENTOR 203	
DATE		DATE		DATE	
		26.01.99.			

SEQUENCE LISTING

<110> Mark Achtman
Monique Moreau

<120> IGA1 PROTEASE FRAGMENT AS CARRIER PEPTIDE

<130> 7101/OE616US0

<140> US 09/142,970

<141> 1998-09-18

<150> EP 97100883.4

<151> 1997-01-21

<150> PCT/EP98/00294

<151> 1998-01-20

<160> 5

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 104

<212> PRT

<213> Neisseria meningitidis

<400> 1

Leu	Tyr	Tyr	Lys	Asn	Tyr	Arg	Tyr	Tyr	Ala	Leu	Lys	Ser	Gly	Gly	Ser
1				5					10					15	
Val	Asn	Ala	Pro	Met	Pro	Glu	Asn	Gly	Gln	Thr	Glu	Asn	Asn	Asp	Trp
			20					25					30		
Ile	Leu	Met	Gly	Ser	Thr	Gln	Glu	Glu	Ala	Lys	Lys	Asn	Ala	Met	Asn
		35					40					45			
His	Lys	Asn	Asn	Gln	Arg	Ile	Ser	Gly	Phe	Ser	Gly	Phe	Phe	Gly	Glu
	50					55				60					
Glu	Asn	Gly	Lys	Gly	His	Asn	Gly	Ala	Leu	Asn	Leu	Asn	Phe	Asn	Gly
65					70					75					80
Lys	Ser	Ala	Gln	Asn	Arg	Phe	Leu	Leu	Thr	Gly	Gly	Thr	Asn	Leu	Asn
				85					90					95	
Gly	Lys	Ile	Ser	Val	Thr	Gln	Gly								
				100											

<210> 2

<211> 104

<212> PRT

<213> Neisseria meningitidis

<400> 2

Leu	Tyr	Tyr	Lys	Asn	Tyr	Arg	Tyr	Tyr	Ala	Leu	Lys	Ser	Gly	Gly	Ser
1				5					10					15	
Val	Asn	Ala	Pro	Met	Pro	Glu	Asn	Gly	Val	Thr	Glu	Asn	Asn	Asp	Trp
			20					25					30		
Val	Phe	Met	Gly	Tyr	Thr	Gln	Glu	Glu	Ala	Lys	Lys	Asn	Ala	Met	Asn
		35					40					45			
His	Lys	Asn	Asn	Gln	Arg	Ile	Ser	Gly	Phe	Ser	Gly	Phe	Phe	Gly	Glu
	50					55				60					
Glu	Asn	Gly	Lys	Gly	His	Asn	Gly	Ala	Leu	Asn	Leu	Asn	Phe	Asn	Gly
65					70					75					80
Lys	Ser	Ala	Gln	Asn	Arg	Phe	Leu	Leu	Thr	Gly	Gly	Thr	Asn	Leu	Asn
				85					90					95	

Gly Lys Ile Ser Val Thr Gln Gly
100

<210> 3
<211> 104
<212> PRT
<213> Neisseria meningitidis

<400> 3
Leu Tyr Tyr Lys Asn Tyr Arg Tyr Tyr Ala Leu Lys Ser Gly Gly Ser
1 5 10 15
Val Asn Ala Pro Met Pro Glu Asn Gly Gln Thr Glu Asn Asn Asp Trp
20 25 30
Val Phe Met Gly Tyr Lys Gln Glu Glu Ala Gln Lys Asn Ala Met Asn
35 40 45
His Lys Asn Asn Gln Arg Ile Ser Gly Phe Ser Gly Phe Phe Gly Glu
50 55 60
Glu Asn Gly Lys Gly His Asn Gly Ala Leu Asn Leu Asn Phe Asn Gly
65 70 75 80
Lys Ser Ala Gln Asn Arg Phe Leu Leu Thr Gly Gly Thr Asn Leu Asn
85 90 95
Gly Lys Ile Ser Val Thr Gln Gly
100

<210> 4
<211> 104
<212> PRT
<213> Neisseria gonorrhoeae

<400> 4
Leu Tyr Tyr Lys Asn Tyr Arg Tyr Tyr Ala Leu Lys Ser Gly Gly Arg
1 5 10 15
Leu Asn Ala Pro Met Pro Glu Asn Gly Val Ala Glu Asn Asn Asp Trp
20 25 30
Val Phe Met Gly Tyr Thr Gln Glu Glu Ala Arg Lys Asn Ala Met Asn
35 40 45
Asn Lys Asn Asn Arg Arg Ile Gly Asp Phe Gly Gly Phe Phe Asp Glu
50 55 60
Glu Asn Gly Lys Gly His Asn Gly Ala Leu Asn Leu Asn Phe Asn Gly
65 70 75 80
Lys Ser Ala Gln Asn Arg Phe Leu Leu Thr Gly Gly Ala Asn Leu Asn
85 90 95
Gly Gly Asn Gly Arg Pro Val Lys
100

<210> 5
<211> 104
<212> PRT
<213> Neisseria gonorrhoeae

<400> 5
Leu Tyr Tyr Lys Asn Tyr Arg Tyr Tyr Ala Leu Lys Ser Gly Gly Arg
1 5 10 15
Leu Asn Ala Pro Met Pro Glu Asn Gly Val Ala Glu Asn Asn Asp Trp
20 25 30
Ile Phe Met Gly Tyr Thr Gln Glu Glu Ala Arg Lys Asn Ala Met Asn
35 40 45
His Lys Asn Asn Arg Arg Ile Gly Asp Phe Gly Gly Phe Phe Asp Glu
50 55 60
Glu Asn Gly Lys Gly His Asn Gly Ala Leu Asn Leu Asn Phe Asn Gly
65 70 75 80
Lys Ser Ala Gln Asn Arg Phe Leu Leu Thr Gly Gly Ala Asn Leu Asn
85 90 95

